New antiarrhythmic treatment of atrial fibrillation

Expert Review of Cardiovascular Therapy

Volumn 5, Issue 4, 2007, Pages 707-714

  Naccarelli, Gerald V ^a   Wohlbrette, Deborah L ^a   Samii, Soraya ^a   Banchs, Javier E ^a   Penny Peterson, Erica ^a   Gonzalez, Mario D ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; Atrial fibrillation; Carvedilol; Dronedarone; Omega 3 fatty acid; Rotigaptide; Statins; Vernakalant

Indexed keywords

2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; ADENOSINE A1 RECEPTOR AGONIST; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ATENOLOL; ATI 2042; AZD 7009; BISOPROLOL; CARDIOVASCULAR AGENT; CARVEDILOL; CELIVARONE; CORTICOSTEROID DERIVATIVE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRONEDARONE; ENZYME INHIBITOR; FISH OIL; HIGH MOBILITY GROUP COENZYME A ENZYME INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUTILIDE; METOPROLOL; OMEGA 3 FATTY ACID; PLACEBO; ROTIGAPTIDE; RSD 1235; SELODENOSON; SSRI 149744C; TECADENOSON; TEDISAMIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERNAKALANT;

ANTIARRHYTHMIC ACTIVITY; BRONCHOSPASM; CARDIOVERSION; CATHETER ABLATION; CLINICAL TRIAL; COUGHING; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG WITHDRAWAL; DYSGEUSIA; GAP JUNCTION; GASTROINTESTINAL SYMPTOM; HEART ATRIUM; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART PROARRHYTHMIA; HUMAN; HYPOTENSION; LIVER TOXICITY; LUNG TOXICITY; MONOTHERAPY; MORTALITY; NAUSEA; NONHUMAN; PARESTHESIA; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PATIENT SELECTION; PRURITUS; QT PROLONGATION; RECURRENT DISEASE; REVIEW; RISK REDUCTION; SIDE EFFECT; SNEEZING; SUSTAINED RELEASE FORMULATION; THYROTOXICOSIS; TORSADE DES POINTES;

ADENOSINE; ADRENERGIC BETA-ANTAGONISTS; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BENZOFURANS; BICYCLO COMPOUNDS, HETEROCYCLIC; BIPHENYL COMPOUNDS; CARBAZOLES; CYCLOPROPANES; FATTY ACIDS, OMEGA-3; FURANS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OLIGOPEPTIDES; ORGANIC CHEMICALS; PEPTIDYL-DIPEPTIDASE A; POTASSIUM CHANNEL BLOCKERS; PROPANOLAMINES; RECEPTOR, ADENOSINE A1; RECEPTORS, PURINERGIC P1;

EID: 34447328696     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.5.4.707     Document Type: Review

References (70)

1. Naccarelli GV, Wolbrette DL, Khan M et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am. J. Cardiol. 91, 15D-26D (2003).
2. Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of atrial fibrillation - executive summary. J. Am. Coll. Cardiol. 48, 854-906 (2006).
3. Ross HM, Kowey PR, Naccarelli GV. New antiarrhythmic pharmacologic therapies and regulatory issues in antiarrhythmic drug development. In: New Arrhythmia Technologies. Wang P (Ed.). Blackwell Publishing, Oxford, UK 3-13 (2005).
4. Naccarelli GV, Lukas M. Carvedilol's antiarrhythmic properties: therapeutic implications in patients with left ventricular dysfunction. Clin. Cardiol. 28, 165-173 2005).
5. Katritsis DG, Panagiotakos DB, Karvouni E et al. Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. Am. J. Cardiol. 92, 1116-1119 (2003).
6. Merritt JC, Niebaur M, Tarakji K, Hammer D, Mills RM. Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation. Am. J. Cardiol. 92, 735-736 (2003).
7. Kanoupakis EM, Manios EG, Mavkaris HE et al. Comparative effects of carvedilol and amiodarone on conversion and recurrence rates of persistent atrial fibrillation. Am. J. Cardiol. 94, 659-662 (2004).
8. Khand AU, Rankin AC, Martin W et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J. Am. Coll. Cardiol. 42, 1944-1951 (2003).
9. Camm AJ, Savelieva I. Advances in antiarrhythmic drug treatment of atrial fibrillation: where do we stand now? Heart Rhythm 1, 244--246 (2004).
10. Singh S. Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation. J. Interv. Card. Electrophys. 10, S71-S76 (2004).
11. Choudhury A, Lip GY. Antiarrhythmic drugs in atrial fibrillation: an overview of new agents, their mechanisms of action and potential clinical utility. Expert Opin. Investig. Drugs 13, 841-855 (2004).
12. Matyus P, Varga I, Rettegi T et al. Novel antiarrhythmic compounds with combined class IB and class III mode of action. Curr. Med. Chem. 11, 61-69 (2004).
13. Castro A. Bianconi L, Santini M. New antiarrhythmic drugs for the treatment of atrial fibrillation. PACE 25, 249-259 (2002).
14. Weiss JN, Garfinkel A, Chen PS. Novel approaches to identifying antiarrhythmic drugs. Trends Cardiovasc. Med. 13, 326-330 (2003).
15. Tamargo J, Caballero R, Delpon E. New mechanistic targets for the treatment of atrial fibrillation. In: Atrial Fibrillation: New Therapeutic Concepts. Papp JP, Straub M, Ziegler D (Eds). IOS Press, Amsterdam, The Netherlands 133-155 (2003).
16. Padanilam B, Prystowsky E. New antiarrhythmics agents for the prevention and treatment of atrial fibrillation. J. Cardiovasc. Electrophysiol. 17(3), S62-S66 (2006).
17. Musco S, Seltzer J, Kowey PR. Future directions in antiarrhythmic drug therapy for atrial fibrillation. Future Cardiol. 2(5), 545-553 (2006).
18. Freestone B, Lip GY. Tedisamil: a novel antiarrhythmic. Expert Opin. Investig. Drugs 13, 151-160 (2004).
19. Hohnloser SH, Dorian P, Straub M, Beckmann K, Kowey P. Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. J. Am. Coll. Cardiol. 44, 99-104 (2004).
20. Fedida D, Orth P, Chen J et al. The mechanism of atrial antiarrhythmic action of RSD1235. J. Cardiovasc. Electrophysiol. 17, S71-S78 (2006).
21. Dorian P, Mangat I, Korley V. The investigational antiarrhythmic agent RSD1235 is atrially selective in humans. Circulation 112, II-94 (2005).
22. Roy D, Rowe BH, Stiell IG et al; for the CRAFT Investigators. A randomized, controlled trial of RSD 1235, a novel antiarrhythmic agent, in the treatment of recent onset atrial fibrillation. J. Am. Coll. Cardiol. 44, 2355-2361 (2004).
23. Roy D, Pratt C, Wyse DG et al. RSD1235 for conversion of atrial fibrillation. The Phase III Atrial Arrhythmia Conversion Trial. Presented at Heart Rhythm Society 2005 26th Annual Scientific Sessions New Orleans, LA, USA 4-7 May 2005.
24. Pratt C, Roy D, Juul-Moller S et al. Efficacy and tolerance of RSD1235 in the treatment of atrial fibrillation or atrial flutter: results of a Phase III, randomized, placebo-controlled, multicenter trial. J. Am. Coll. Cardiol. 47, 10A (2006) (Abstract).
25. Pratt CM, Navratil J, Nagy A et al. Oral vernakalant (RSD1235-SR) prevents recurrence of atrial fibrillation following cardioversion. Heart Rhythm 4, S176 (2007) (Abstract).
26. Goldstein RN, Khrestian C, Carlsson L, Waldo AL. AZD7009: a new antiarrhythmic drug with predomiant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J. Cardiovasc. Electrophysiol. 15, 1444-1450 (2004).
27. Geller CJ, Crijns HJ, Egstrup K et al. Pharmacological conversion with intravenous AZD7009 is as effective as DC cardioversion in patients with persistent atrial fibrillation lasting <30 days. Heart Rhythm 4, S178 (2007) (Abstract).
28. Blaauw Y, Gogelein H, Tieleman RG, van Hunnik A, Schotten U, Allessie MA. "Early" class III drugs for the treatment of atrial fibrillation. Efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation. 110, 1717-1724 (2004).
29. de Haan S, Greiser M, Harks E et al. AVE0118, Blocker of the transient outward current (Ito) and ultrarapid delayed rectifier current (IKur), fully restores atrial contractility after cardioversion of atrial fibrillation in the goat. Circulation. 114, 1234-1242 (2006).
30. Hynes J, Wolbrette DL, Luck JC, Khan M, Samii S, Naccarelli GV. A review of the pharmacokinetics, electrophysiology and clinical efficacy of dronedarone. Future Cardiol. 1, 135-144 (2005).
31. Tafreshi MJ, Rowles J. A review of the investigational antiarrhythmic agent dronedarone. J. Cardiovasc. Pharmacol. Ther. 12, 15-26 (2007).
32. Dale KM, White CM. Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann. Pharm. 41, 599-605 (2007).
33. Sun W, Sarma JSM, Singh BN. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart. Comparison with amiodarone. Circulation 100, 2276-2281 (1999).
34. Touboul P, Brugada J, Capucci A et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur. Heart J. 24, 1481-1487 (2003).
35. Singh BN, Hohnloser SH, Connolly SJ et al. The EURIDIS and ADONIS Trials: dronedarone for maintaining sinus rhythm in patients with atrial fibrillation/flutter. Circulation 110(Suppl.), III-741 (2003) (Abstract).
36. Sun W, Sarma JSM, Singh BN. Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone. J. Cardiovasc. Pharmacol. 39, 677-684 (2002).
37. Gauthier P, Guillemare E, Marion A et al. Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. J. Cardiovasc. Pharmacol. 41, 191-202 (2003).
38. Varro A, Takacs J, Nemeth M et al. Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone. Br. J. Pharmacol. 133, 625-634 (2001).
39. Tschuppert Y, Buclin T, Rothuizen LE et al. Effect of dronedarone on renal function in healthy subjects. Clin. Pharmacol. Ther. 2, P10-P19 (2005).
40. Davy JM. Dronedarone demonstrates additional rate control on top of standard pharmacotherpaies in the treatment of atrial fibrillation. Circulation 112, II-577 (2005).
41. Hohnloser SH. Dronedarone significantly decreases the combined endpoint of hospitalization and death in atrial fibrillation. Circulation 112, II-327 (2005) (Abstract).
42. Kowey PR, Aliot EM, Capucci A et al. Placebo-controlled double-blind dose-ranging study of the efficacy and safety of SSR149744C in patients with recent atrial fibrillation/flutter. Heart Rhythm 4, S72 (2007) (Abstract).
43. Ellenbogen K, O'Neill G, Prystowsky E et al. Trial to evaluate the management of paroxysmal supraventricular tachycardia during an electrophysiology study with tecadenoson. Circulation 111, 3202-3208 (2006).
44. Gollob MH, Jones DL, Krahn AD et al. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N. Engl. J. Med. 354, 2677-2688 (2006).
45. Haugan K, Olsen K, Hartvig L et al. The antiarrhythmic peptide analog ZP123 prevents atrial conduction slowing during metabolic stress. J. Cardiovasc. Electrophysiol. 16, 537-545 (2005).
46. Guerra J, Everett IVT, Lee K, Wilson E, Olgin J. Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation. Circulation 114, 110-118 (2006).
47. Shiroshita-Takeshita A, Sakabe M, Haughan K, Hennan JK, Nattel S. Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs. Circulation 115, 310-318 (2007).
48. Ehrlich J, Hohnloser S, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur. Heart J. 27, S12-S18 (2006).
49. Pederson OD, Bagger H, Kober L, Torp-Pedersen C. Trandolopril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100, 376-380 (1999).
50. Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am. Heart J. 151, 217-222 (2006).
51. Ueng, K-C, Tsung-Po T, Wen-Chung Y et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Eur. Heart J. 24, 2090-2098 (2003).
52. Murray KT, Rottman JN, Arbogast PG et al, and the AFFIRM Investigators. Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm 1, 669-675 (2004).
53. Madrid AH, Bueno MG, Rebollo JMG et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. A prospective and randomized study. Circulation 106, 331-336 (2002).
54. Wachtell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol. J. Am. Coll. Cardiol. 45, 712-719 (2005).
55. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling. J. Am. Coll. Cardiol. 41, 2197-2204 (2003).
56. The ACTIVE Steering Committee. Rationale and design of ACTIVE: the atrial fibrillation clopidogrel with irbesartan for prevention of vascular events. Am. Heart J. 151, 1187-1193 (2006).
57. Young-Xu Y, Jabbour S, Goldberg R et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am. J. Cardiol. 92, 1379-1383 (2003).
58. Ozaydin M, Varol E, Asian S et al. Effect of atorvastatin on the recurrence of atrial fibrillation after electrical cardioversion. Am. J. Cardiol. 97, 1490-1493 (2006).
59. Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am. J. Cardiol. 92, 1343-1345 (2003).
60. Patti G, Chello M, Candura D et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery. Results of the ARMDYA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia After cardiac surgery) study. Circulation 114, 1455-1461 (2006).
61. Marin F, Pascual DA, Roldan V et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am. J. Cardiol. 97, 55-60 (2006).
62. 2+ currents by polyunsaturated fatty acids in adult and neonatal rat ventricular myocytes. Proc. Natl. Acad. Sci. USA 94, 4182-4187 (1997).
63. Dhein S, Michaelis B, Mohr FW. Antiarrhythmic and electrophysiological effects of long-chain omega-3 polyunsaturated fatty acids. Arch. Pharmacol. 371, 202-211 (2005).
64. Ninio DM, Murphy KJ, Howe PR, Saint DA. Dietary fish oil protects against stretch-induced vulnerability to atrial fibrillation in a rabbit model. J. Cardiovasc. Electrophysiol. 16, 1189-1194 (2005).
65. Reiffel JA, McDonald A. Antiarrhythmic effects of omega-3 fatty acids. Am. J. Cardiol. 98, 50i-60i (2006).
66. Mozaffarian D, Psaty B, Rimm E et al. Fish intake and risk of incident atrial fibrillation. Circulation 110(4), 367-373 (2004).
67. Mozaffarian D, Prineas RJ, Stein PK, Siscovick DS. Dietary fish and n-3 fatty acid intake and cardiac electrophysiology parameters in humans. J. Am. Coll. Cardiol. 48, 478-484 (2006).
68. Calo L, Bianconi L, Colivicchi F et al. N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery. J. Am. Coll. Cardiol. 45, 1723-1728 (2005).
69. Biscione F, Totteri A, De Vita A. Effect of omega-3 fatty acids on the prevention of atrial arrhythmias. Ital. Heart J. 6, 53-59 (2005).
70. Brouwer IA, Heeringa J, Geleinse JM et al. Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam Study. Am. Heart J. 151, 857-862 (2006).